Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 19 studies | 45% ± 12% | |
lung | 18 studies | 48% ± 15% | |
intestine | 13 studies | 40% ± 17% | |
brain | 9 studies | 31% ± 15% | |
kidney | 9 studies | 50% ± 11% | |
eye | 8 studies | 32% ± 9% | |
liver | 7 studies | 37% ± 13% | |
bone marrow | 6 studies | 32% ± 17% | |
pancreas | 5 studies | 58% ± 21% | |
placenta | 5 studies | 46% ± 27% | |
lymph node | 5 studies | 46% ± 16% | |
uterus | 4 studies | 52% ± 15% | |
prostate | 4 studies | 33% ± 6% | |
breast | 4 studies | 57% ± 11% | |
adipose | 3 studies | 31% ± 7% | |
adrenal gland | 3 studies | 41% ± 5% | |
esophagus | 3 studies | 57% ± 22% | |
skin | 3 studies | 51% ± 16% | |
thymus | 3 studies | 60% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 9152.92 | 226 / 226 | 100% | 214.80 | 406 / 406 |
brain | 100% | 6737.00 | 2639 / 2642 | 100% | 629.36 | 705 / 705 |
bladder | 100% | 3137.95 | 21 / 21 | 100% | 205.03 | 502 / 504 |
prostate | 100% | 6895.56 | 244 / 245 | 100% | 380.67 | 501 / 502 |
skin | 100% | 8475.64 | 1809 / 1809 | 99% | 178.25 | 469 / 472 |
breast | 100% | 7758.51 | 459 / 459 | 99% | 239.77 | 1107 / 1118 |
stomach | 99% | 3181.97 | 356 / 359 | 100% | 163.74 | 285 / 286 |
thymus | 98% | 3288.29 | 642 / 653 | 100% | 169.96 | 604 / 605 |
kidney | 100% | 10479.61 | 89 / 89 | 97% | 126.79 | 878 / 901 |
lung | 98% | 4609.74 | 569 / 578 | 99% | 162.94 | 1143 / 1155 |
intestine | 98% | 4381.99 | 945 / 966 | 99% | 180.74 | 524 / 527 |
esophagus | 97% | 6229.98 | 1402 / 1445 | 99% | 127.19 | 182 / 183 |
ovary | 89% | 1762.36 | 161 / 180 | 91% | 78.33 | 391 / 430 |
uterus | 81% | 1648.72 | 137 / 170 | 99% | 190.51 | 455 / 459 |
pancreas | 81% | 1583.05 | 265 / 328 | 98% | 137.75 | 175 / 178 |
adrenal gland | 100% | 3417.50 | 257 / 258 | 73% | 57.33 | 168 / 230 |
adipose | 100% | 7444.72 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 276.08 | 29 / 29 |
tonsil | 0% | 0 | 0 / 0 | 100% | 254.55 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 105.79 | 1 / 1 |
spleen | 100% | 2612.40 | 240 / 241 | 0% | 0 | 0 / 0 |
heart | 97% | 6240.50 | 835 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 97% | 2676.33 | 1290 / 1335 | 0% | 0 | 0 / 0 |
muscle | 81% | 2066.73 | 653 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 81% | 57.82 | 65 / 80 |
peripheral blood | 37% | 3416.99 | 345 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2001140 | Biological process | positive regulation of phospholipid transport |
GO_0036151 | Biological process | phosphatidylcholine acyl-chain remodeling |
GO_1903060 | Biological process | negative regulation of protein lipidation |
GO_0006631 | Biological process | fatty acid metabolic process |
GO_1905920 | Biological process | positive regulation of CoA-transferase activity |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0070062 | Cellular component | extracellular exosome |
GO_0032994 | Cellular component | protein-lipid complex |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0030156 | Molecular function | benzodiazepine receptor binding |
GO_0036042 | Molecular function | long-chain fatty acyl-CoA binding |
GO_0000062 | Molecular function | fatty-acyl-CoA binding |
GO_0042802 | Molecular function | identical protein binding |
Gene name | DBI |
Protein name | Acyl-CoA-binding protein Acyl-CoA-binding protein (ACBP) (Diazepam-binding inhibitor) (DBI) (Endozepine) (EP) |
Synonyms | |
Description | FUNCTION: Binds medium- and long-chain acyl-CoA esters with very high affinity and may function as an intracellular carrier of acyl-CoA esters. It is also able to displace diazepam from the benzodiazepine (BZD) recognition site located on the GABA type A receptor. It is therefore possible that this protein also acts as a neuropeptide to modulate the action of the GABA receptor. |
Accessions | P07108 ENST00000355857.8 [P07108-1] ENST00000409094.5 [P07108-2] ENST00000535757.5 [P07108-2] B8ZWD8 ENST00000393103.2 [P07108-3] ENST00000627305.2 [P07108-5] B8ZWD1 ENST00000311521.8 [P07108-2] B8ZWD9 ENST00000627093.2 [P07108-4] ENST00000535617.5 |